Información:
Error:
ID
34177
Descripción
Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers; ODM derived from: https://clinicaltrials.gov/show/NCT02098954
Link
https://clinicaltrials.gov/show/NCT02098954
Palabras clave
Versiones (1)
- 15/1/19 15/1/19 -
Titular de derechos de autor
GSK group of companies
Subido en
15 de enero de 2019
DOI
Para solicitar uno, por favor iniciar sesión.
Licencia
Creative Commons BY-NC 3.0
Comentarios del modelo :
Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.
Comentarios de grupo de elementos para :
Comentarios del elemento para :
Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.
Eligibility Carcinoma, Non-Small Cell Lung NCT02098954
Eligibility Carcinoma, Non-Small Cell Lung NCT02098954
- StudyEvent: Eligibility
Similar models
Eligibility Carcinoma, Non-Small Cell Lung NCT02098954
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
ID.1
Item
advanced non-small cell lung cancer, stage iiib/iv
boolean
ID.2
Item
non-squamous
boolean
ID.3
Item
egfr sensitive mutations, such as exon 19 del, or exon 21 l858r
boolean
ID.4
Item
received first line tkis treatment and developed tki resistance
boolean
ID.5
Item
ecog 0-2
boolean
ID.6
Item
squamous non-small cell lung cancer
boolean
ID.7
Item
patients have unstable brain metastasis, predict survival less than 8 weeks
boolean
ID.8
Item
spinal-cord compression without evidence of stabilisation or treatment
boolean
ID.9
Item
women who were pregnant or lactating; women with a positive or no available pregnancy test result at baseline
boolean
ID.10
Item
patients have any unstable illness that could not receive further treatment
boolean